SETD2 and central nervous system cancer: These included ERBB2 in LUAD (70% mean CCP), NFE2L2 in LUAD (78%, compared to 92% in LUSC), ARID1A in lower grade glioma (55%), and multiple genes in KIRC (PTEN, 77%; SETD2, 68%; TP53, 51%; ARID1A, 37%).